|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date21 May 2021 |
|
MechanismRSV L protein inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Johnson & Johnson Pharmaceuticals Co., Ltd.
0 Patents (Medical) associated with Johnson & Johnson Pharmaceuticals Co., Ltd.
100 Deals associated with Johnson & Johnson Pharmaceuticals Co., Ltd.
100 Translational Medicine associated with Johnson & Johnson Pharmaceuticals Co., Ltd.